The Effect of Acipimox on GLP-1 Secretion in Healthy Subjects: a Pilot Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Aarhus
- Enrollment
- 8
- Locations
- 1
- Primary Endpoint
- Levels of GLP-1 in plasma
Study Overview
Brief Summary
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus). Recently it was found, that levels of GLP-1 are increased in response to acipimox. The hypothesis is that G protein coupled receptors on enteroendocrine L cells bind acipimox and thereby induce GLP-1 secretion.
In a controlled, open, randomized experiment, eight healthy, overweight men will be studied on an intervention day, where they receive acipimox, and on a control day. The study day includes an OGTT (oral glucose tolerance test), blood samples before and after the OGTT and a biopsy from adipose tissue.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to 50 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Adult men
- •BMI 25-35
Exclusion Criteria
- •Known DM2
- •Receiving hypolipidemic drugs
Arms & Interventions
Acipimox
Administration of acipimox 250 mg p.o.
Intervention: Acipimox (Drug)
Outcomes
Primary Outcomes
Levels of GLP-1 in plasma
Time Frame: 9 months
Secondary Outcomes
- Lipolytic activity in adipose tissue by measuring FFA (free fatty acid) levels(9 months)
- Insulin sensitivity by measuring blood glucose after an OGTT(5 months)